NCT00002004已完成1 期
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To assess pharmacokinetic properties of rCD4 in humans. To obtain a preliminary indication of the antiviral effects of rCD4 in patients with AIDS and AIDS related complex (ARC).
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related ComplexHIV InfectionsNCT00002005Genentech, Inc.
已完成
1 期
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related ComplexHIV InfectionsNCT00000675National Institute of Allergy and Infectious Diseases (NIAID)60
已完成
1 期
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related ComplexHIV InfectionsNCT00000976National Institute of Allergy and Infectious Diseases (NIAID)40
已完成
1 期
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)Merkel Cell CarcinomaNCT05422781Immunomic Therapeutics, Inc.6
已完成
1 期
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 InfectionHuman Immunodeficiency VirusNCT01734850Calimmune, Inc.13